Open Access

Antiarrhythmic drugs in out-of-hospital cardiac arrest: is there a place for potassium chloride?

Critical Care201721:144

https://doi.org/10.1186/s13054-017-1732-z

Published: 17 June 2017

The original article was published in Critical Care 2017 21:59

In the March 2017 issue of Critical Care, Tagami et al. [1] emphasized that amiodarone, lidocaine, and nifekalant similarly improve survival at hospital admission for out-of-hospital cardiac arrest (OHCA) patients due to refractory ventricular fibrillation (VF). However, neither amiodarone nor lidocaine has been shown to improve long-term survival or neurologic recovery [2].

During resuscitation, the main objective of cardiopulmonary resuscitation is to maintain blood flow pending etiological treatment, and to try and restore sinus rhythm [3]. Antiarrhythmic drugs work on sodium, calcium, and/or potassium channels, and therefore modify the defibrillation threshold [1]. Amiodarone induces a prolonged hypotension, this effect being mainly linked to its solvent, whereas lidocaine causes a concentration-dependent increase in defibrillation energy requirements and a negative inotropic effect. However, according to current guidelines, antiarrhythmic drugs should be administered during the metabolic phase of cardiac arrest, which is paradoxically the most unfavorable phase for their efficiency [3].

Potassium chloride (KCl) is the major component of cardioplegia solutions used to arrest the heart during cardiac surgery under extracorporeal life support (ECLS). This effect is fully reversible, enabling return of spontaneous circulation after its administration. Twenty-five years ago, Beyersdorf et al. [4] observed that administration of a high-potassium solution could salvage cardiac arrest patients due to an irreversible VF. This report suggested that KCl injection could be an alternative to conventional antiarrhythmic drugs during the metabolic phase of cardiac arrest due to irreversible VF. As evidence, direct intravenous KCl injection was recently shown efficient to stop refractory VF in a patient under continuous ECLS: a few minutes after KCl administration, the heart recovered a hemodynamically efficient normal sinus rhythm [5].

In cardiac arrest due to refractory VF, the proposition of direct intravenous KCl injection can primarily be surprising, because there is a suspected ischemia–reperfusion syndrome with metabolic acidosis and thus hyperkalemia, underlying the use of the pure potassium blocker nifekalant [1]. Conversely, we must keep in mind that medical resuscitation using a beta-agonist drug (epinephrine) and sodium bicarbonate can induce transfer hypokalemia. Moreover, the latter can be deleterious on membrane stabilization, and can consecutively sustain ventricular dysrhythmia. Elsewhere, unlike amiodarone or lidocaine, KCl administration is not responsible for a persistent negative inotropic effect.

Investigating the efficacy of direct intravenous KCl injection for OHCA due to irreversible VF seems therefore to be a relevant research pathway, to define the potential benefit of this treatment in the therapeutic strategy as compared with conventional antiarrhythmic drugs.

Notes

Abbreviations

ECLS: 

Extracorporeal life support

KCl: 

Potassium chloride

OHCA: 

Out-of-hospital cardiac arrest

VF: 

Ventricular fibrillation

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

RJ drafted the manuscript. BV revised the manuscript. Both authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
SAMU de Paris, Service d’Anesthésie Réanimation, Hôpital Necker—Enfants Malades, Assistance Publique—Hôpitaux de Paris, and Université Paris Descartes—Paris 5

References

  1. Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care. 2017;21(1):59.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;374(18):1711–22.View ArticlePubMedGoogle Scholar
  3. Soar J, Nolan JP, Bottiger BW, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015;95:100–47.View ArticlePubMedGoogle Scholar
  4. Beyersdorf F, Kirsch M, Buckberg GD, Allen BS. Warm glutamate/aspartate enriched blood cardioplegic solution for perioperative sudden death. J Thorac Cardiovasc Surg. 1992;104(4):1141–7.PubMedGoogle Scholar
  5. Jouffroy R, Lamhaut L, Philippe P, An K, Carli P, Vivien B. A new approach for treatment of refractory ventricular fibrillation allowed by extra corporeal lifesupport (ECLS)? Resuscitation. 2014;85(8):e118.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement